Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model

Autor(es)

Rici, R. E. G. ^[1] ; Will, S. E. A. L. ^[2] ; Luna, A. C. L. ^[2] ; Melo, L. F. ^[1] ; Santos, A. C. ^[1] ; Rodrigues, R. F. ^[1] ; Leandro, R. M. ^[1] ; Maria, D. A. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Vet Med & Anim Sci, Av Prof Dr Orlando Marques de Paiva 87, BR-05508270 Sao Paulo, SP - Brazil

^[2] Butantan Inst, Lab Biochem & Biophys, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: VETERINARY AND COMPARATIVE ONCOLOGY; v. 16, n. 4, p. 478-488, DEC 2018.
• Citações Web of Science: 1

Resumo

Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP-2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP-2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb-c/nude with MSCs, rhBMP-2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP-2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP-2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy. (AU)

• Processo FAPESP: 12/21191-6 - Células tronco mesenquimais (CTM) e proteína morfogenética (rhBMP-2) associada a quimioterapia: uma nova perpectiva para a terapia do osteossarcoma canino
• Beneficiário: Rose Eli Grassi Rici
• Modalidade de apoio: Auxílio à Pesquisa - Regular